Modern Medicine: The Basics of Biotech and How You Can Invest

Modern medicine

Fun fact: the average life expectancy of an American citizen was 79 years in 2011. That’s not too shabby! And it is even more impressive when you realize that’s a 30 year increase from only 49 years in 1900. If they had twitter back then, #carpediem would be trending 24/7.

That amazing increase in average life expectancy begs the question, “Why?”

The answer is not so simple. Researchers link the increase to a smorgasbord of causes, including improvements in nutrition and sanitation and a general increase in wealth. However, one factor stands out amongst them all: advancements in medical treatment. ????

This is where the biotechnology investment available on Stash called Modern Meds comes into play.

Ancient Art Turned Modern Medicine

Modern Meds is about biotechnology. Biotechnology might seem like a complex, scientific concept, but you are probably already familiar with one of its chief inventions: bread. Yes, bread! ???? That, in a nutshell, is what biotechnology is — using the natural (biological) processes of microorganisms (like yeast) to create foods, genetically enhanced crops, or — in the case of Modern Meds — life-saving medicine.

Biotechnology, pharmaceuticals …????  po-tay-to, po-tah-to, right?

Well, sort of. Historically the difference between biotech and pharma has been in the materials used to create the drugs. Biotech companies use organic material (microorganisms), while pharmaceutical companies use chemicals. However, this distinction has blurred as pharmaceutical companies expand the scope of their research and investment.

These days, the difference is more related to the size of the firms. Just take a look at the top companies by market cap from both industries and you’ll find that biotechnology firms are smaller than their pharmaceutical counterparts, on average. One reason for this is simple — staying small and scrappy allows biotechnology firms to circumvent chains of corporate bureaucracy and pursue innovative breakthroughs. In fact, 64% of FDA approved drugs in 2015 came from smaller biopharma firms. The proof is in the biological pudding. ????????

The Not So Usual Suspects

When you invest in Modern Meds, you invest in companies like Ariad Pharmaceuticals, Clovis Ocology, Arcadia Pharmaceuticals, and Vertex Pharmaceuticals. Haven’t heard of them? Well, consider yourself lucky, because these companies deal with the worst of the worst when it comes to disease. Their drugs, some FDA approved, others in clinical trials, are for patients afflicted by diseases like leukemia, bone sarcoma, lung cancer, ovarian cancer, breast cancer, hepatitis C, and Parkinson’s Disease.

Fight the Good Fight with this Biotech ETF????????

modern medicine

That’s where you come in. If you want to work toward eradicating lethal illnesses from the face of the planet, this ETF (Exchange-Traded Fund) might be for you. However, attaining that vision doesn’t come without risks.

The clinical trial process required to get FDA approval is both costly and unpredictable. For every hundred drugs that start the clinical trial process, only eight will ever see the light of day. Even for the drugs that get approved, there is still the risk of liability lawsuits, technological change, and patent defensibility.

However, these risks can come with rewards. Despite the volatility of the biotechnology industry, if all goes well, these companies have a product that only they can sell and that consumers desperately need — which is often a recipe for high profits. If prospective investors can stomach the highs and lows that biotechnology brings, then it could be a good addition to a diversified portfolio.

Want a more microscopic look?

We recommend that you do your own research about the underlying ETF, SPDR S&P Biotech, on the fund’s website. As always, it’s important to keep an eye on the expense ratio, dividend yield, and the risk-return profile of the investment.







Disclaimers
This material has been distributed for informational and educational purposes only, represents an assessment of the market environment as of the date of publication, is subject to change without notice, and is not intended as investment, legal, accounting, or tax advice or opinion. StashInvest assumes no obligation to provide notifications of changes in any factors that could affect the information provided. This information should not be relied upon by the reader as research or investment advice regarding any issuer or security in particular. The strategies discussed are strictly for illustrative and educational purposes and should not be construed as a recommendation to purchase or sell, or an offer to sell or a solicitation of an offer to buy any security. There is no guarantee that any strategies discussed will be effective.

Furthermore, the information presented does not take into consideration commissions, tax implications, or other transactional costs, which may significantly affect the economic consequences of a given strategy or investment decision. This information is not intended as a recommendation to invest in any particular asset class or strategy or as a promise of future performance. There is no guarantee that any investment strategy will work under all market conditions or is suitable for all investors. Each investor should evaluate their ability to invest long term, especially during periods of downturn in the market. Investors should not substitute these materials for professional services, and should seek advice from an independent advisor before acting on any information presented.

Past performance does not guarantee future results. There is a potential for loss as well as gain in investing. StashInvest does not represent in any manner that the circumstances described herein will result in any particular outcome. While the data and analysis StashInvest uses from third party sources is believed to be reliable, StashInvest does not guarantee the accuracy of such information. Nothing in this article should be considered as a solicitation or offer, or recommendation, to buy or sell any particular security or investment product or to engage in any investment strategy. No part of this material may be reproduced in any form, or referred to in any other publication, without express written permission. StashInvest does not provide personalized financial planning to investors, such as estate, tax, or retirement planning. Investment advisory services are only provided to investors who become StashInvest Clients pursuant to a written Advisory Agreement. For more information please visit www.stashinvest.com/disclosures.

The SPDR S&P Biotech ETF (symbol: XBI) seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index, a modified equal weight index, represents the biotechnology sub-industry portion of the S&P Total Markets Index, which tracks all the U.S. common stocks listed on the NYSE, AMEX, NASDAQ National Market and NASDAQ Small Cap exchanges. XBI invests by sampling the Index, holding a range of securities that, in the aggregate, approximates the full Index in terms of key risk factors and other characteristics. This may cause the fund to experience tracking errors relative to performance of the Index. However, in general, ETFs can be expected to move up or down in value with the value of the applicable index. Moreover, because of their narrow focus, sector funds tend to be more volatile than funds that diversify across many sectors and companies. Before investing in any fund, consider its investment objectives, risks, charges and expenses.